Miracle cures are few and far between. The best one can hope for is partial relief. So it is with Sanofi’s consumer health split. The French pharma group’s sale of a majority 50 per cent stake in its Opella unit to Clayton Dubilier & Rice leaves all participants with some ills to address.
奇蹟般的治療方法少之又少。人們所能期待的最好結果也只是部分緩解。賽諾菲的消費者健康業務分拆也是如此。這家法國製藥集團將其Opella部門50%的多數股權出售給Clayton Dubilier & Rice公司後，所有參與者都面臨著一些亟待解決的問題。
您已閱讀12%（415字），剩餘88%（3051字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。